Anhui Zhongsheng Traceability Biotechnology

Nuwacell is a clinical-stage biotechnology company specializing in the development of standardized human induced pluripotent stem cell (iPSC) therapies. Founded by Dr. Shijun Hu and a team of scientists, the company has established a large-scale automated iPSC production platform and a comprehensive library of clinical-grade iPSC lines. Nuwacell's pipeline focuses on high-incidence diseases including Parkinson's disease, diabetes, and various cancers, utilizing differentiated cells such as dopaminergic neurons and NK cells. The company is a leader in the Chinese regenerative medicine sector, operating multiple GMP-compliant manufacturing facilities to support its clinical programs.